Israel
Scala Biodesign, founded in 2022 and headquartered in Israel, is redefining the landscape of protein design with its "One-shot protein design software." Positioned at the intersection of AI, Biotechnology, and Machine Learning, Scala offers a revolutionary no-code platform that allows R&D teams to streamline their protein design process, optimizing success rates and expediting market entry.
The company boasts an impressive foundation laid by its team from the Weizmann Institute of Science, underlined by over 130 peer-reviewed publications and extensive collaborations with 80 commercial and academic partners. Scala’s breakthrough achievements include pioneering the one-shot design of a malaria vaccine candidate now in Phase II trials, marking a significant leap in biotherapeutics and other bio-based applications.
Scala's market penetration is underscored by partnerships with five of the leading twenty pharmaceutical giants. The company recently closed a $5.50M Seed Round on 11 September 2023, with investments from Intel Capital and TLV Partners, signifying strong investor confidence in its disruptive potential.
